Aims/hypothesis This study is a 19 year observational follow-up of a pragmatic open multicentre clusterrandomised controlled trial of 6 years of structured personal diabetes care starting from diagnosis. Methods A total of 1,381 patients aged ≥40 years and newly diagnosed with type 2 diabetes were followed up in national registries for 19 years. Clinical follow-up was at 6 and 14 years after diabetes diagnosis. The original 6 year intervention included regular follow-up and individualised goal setting, supported by prompting of doctors, clinical guidelines, feedback and continuing medical education (ClinicalTrials.gov NCT01074762). The registry-based endpoints were: incidence of any diabetes-related endpoint; diabetes-related death; all-cause mortality; myocardial infarction (MI); stroke; peripheral vascular disease; and microvascular disease.
Introduction
Strict control of blood glucose [1, 2] , BP [3, 4] or lipids [5] lowers the risk of diabetes complications, and a long-term legacy effect of intervention started at diabetes diagnosis has been proposed [6] . Although assessments of the quality of diabetes care continue to show suboptimal management [7, 8] , the benefit of pursuing intensive glucose control in all patients to reduce cardiovascular disease has been questioned [9] [10] [11] [12] . In response to this, the European Association for the Study of Diabetes (EASD) and the ADA, in a joint position statement, have recommended individualising both treatment goals and choice of pharmacological intervention in the management of hyperglycaemia [13] . The application of evidence-based but individualised treatment schemes in daily clinical practice may be tested through multifactorial interventions, targeting health professionals, which have been shown to improve process measures and risk factors in primary care [14] . The effects of such complex interventions on cardiovascular and microvascular outcomes are, however, largely unknown.
The Diabetes Care in General Practice (DCGP) study [15] was a randomised controlled 6 year trial to assess the effect on mortality and morbidity of structured personal care compared with routine care in a population-based sample of patients newly diagnosed with clinical type 2 diabetes. This 19 year follow-up of the DCGP study assessed the long-term effectiveness of 6 years of structured personal diabetes care that was started at diagnosis in primary care. Outcomes were mortality as well as cardiovascular and microvascular complications.
Methods

Study design
The DCGP was a pragmatic open clusterrandomised controlled trial (ClinicalTrials.gov NCT01074762) [15] . Of 1,902 general practitioners invited to participate in 1988, 474 (24.9%) volunteered (Fig. 1) . Their practices were allocated, by random numbers, to give patients either structured personal care or routine care. A detailed description of the study design has been reported previously [15] . The study was approved by the research ethics committee of Copenhagen and Frederiksberg and informed consent was given by all patients.
Patients The doctors were to include all of those on their practice list who were aged 40 or older and newly diagnosed with diabetes between 1 March 1989 and 28 February 1991.
In the third year, 71 doctors in the structured-personal-care group on invitation volunteered to recruit patients for a further year (Fig. 1) . These patients received the same intervention as the other patients in the structured-care group. Following recruitment, diagnosis was confirmed by a single fasting whole-blood/plasma glucose concentration ≥7.0/8.0 mmol/l, measured at a major laboratory. Patients who were diagnosed during hospitalisation were also considered for inclusion. The protocol-based exclusion criteria were life-threatening somatic disease, severe mental illness or unwillingness to participate. For the present analyses, we excluded patients whose diagnosis was not confirmed at a major laboratory within 500 days of diagnosis [15] . Of 1,381 patients in the final study population, 1,369 (99.1%) were of Western European descent. Based on onset of insulin treatment, approximately 97.5% of the patients were considered to have type 2 diabetes.
Intervention In Denmark, routine care for standard type 2 diabetes is usually managed in primary care, with costs covered by the free tax-based health insurance system. In the intervention group, follow-up every 3 months and annual screening for diabetes complications were supported by sending a questionnaire to the general practitioner 1 month before the next expected consultation [15] . The general practitioner was requested to define, together with the patient, the best possible goals, within three predefined categories of 'good', 'acceptable' and 'poor' control, for important risk factors, with emphasis on glycaemic control (Table 1) . At each quarterly consultation, the general practitioner was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. In overweight patients, the general practitioner was prompted to get agreement on a small realistic weight reduction, record it and follow up accordingly. However, participants were not required to target a specific relative body weight.
The general practitioners were introduced to possible solutions to therapeutic problems through six annual half-day seminars, annual descriptive feedback reports on individual patients, and folders and leaflets for doctors and patients. Generally, the importance of diet was stressed and doctors were recommended to postpone, if possible, the start of glucose-lowering drugs until at least 3 months after diabetes diagnosis to observe the effect of any weight loss. It was suggested that the general practitioners recommend increased physical exercise and simple dietary rules: to increase complex carbohydrate to at least 50% of the diet and, in particular, to increase water-soluble fibre; to reduce fat content to a maximum of 30%; to reduce alcohol intake; and to eat five or six meals a day. In cases of persistent hyperglycaemia, metformin was recommended for patients who were overweight by clinical judgment, and glipizide or glibenclamide was suggested for patients of normal weight. In patients aged >70 years, tolbutamide was recommended. If the goal for blood glucose was not met, a combination of metformin and a sulfonylurea was suggested as the last step before starting insulin. To treat hypertension, ACE inhibitors or β blockers were recommended for most patients, but furosemide (frusemide) was preferred for patients with heart failure, and thiazides for patients aged >70 years. Lipid-lowering drugs were recommended for diet-resistant dyslipidaemia. No patient-specific advice on treatment was given to doctors, who were allowed to deviate from the recommendations in an effort to individualise treatment. The patients were never approached by the study centre.
Doctors in the routine-care group were free to choose any treatment and change it over time [15] . The study coordinating centre did not contact routine-care practices during the trial period after inclusion had stopped. On 26 September 1995, the intervention was terminated. No further attempt was made to maintain patients in randomised groups or to influence their therapy. Clinical follow-up examinations 6 and 14 years after diagnosis Approximately 6 and 14 years after diabetes diagnosis, on 26 September 1995 and 31 October 2003, the general practitioners of all surviving patients were asked to do a follow-up examination (Fig. 1 ). The doctors recorded the following information: body weight, BP, drug treatment, severe hypoglycaemic events, number of consultations the preceding year and if the patient had ever been treated at a diabetes clinic. In questionnaires, patients gave information about smoking habits and physical activity in their leisure time. Fasting blood samples were collected at diagnosis and at the follow-up examinations and were analysed at Odense University Hospital; freshly voided morning urine samples were analysed at Århus University Hospital. Throughout the study, the fraction of HbA 1c was determined by the same ion-exchange HPLC protocol. The reference interval was calculated after analysis of samples from 100 blood donors (age 20-80 years, 33 men, 67 women) to be 5.4-7.4% (mean±2 SD). Quality assurance was obtained with commercial control preparations from BioRad. The means of low-and high-control samples were 6.7% (0.31%) and 10.4% (0.63%), respectively, resulting in CVs of 4.6% and 6.0% (CV=SD× 100/mean). This method was later compared with a newer HPLC method (using an automated HbA 1c analyser, Tosoh G7), which was aligned with the DCCT using calibrators from the European Reference Laboratory for Glycated Haemoglobin (ERL). The association between the two methods is approximately linear (R 2 0.9049, n = 484, p<0.0001), and is expressed by the following algorithm: current method = 0.268 + 1.072 × DCCT-aligned method. Although it is impossible to convert individual measurements made using the current method to the newer method, the reference range of the current method (5.4-7.4%) may, with caution, be converted to 4.8-6.7% (29-50 mmol/mol), which corresponds approximately to DCCT values. A description of other variables and definitions has previously been published [15] .
The 6 and 14 year clinical follow-up examinations were done for 970 (93.4%) and 539 (92.1%) of 1,039 and 585 surviving patients, respectively (Fig. 1 ). Because patients moved or new doctors joined or took over a practice, 147 new doctors joined the study during the first 6 years and a further 114 new doctors volunteered for the 14 year followup. The clustering of patients according to general practitioners and the number of patients who moved to a doctor outside the original randomisation arm throughout the trial are given in ESM Tables 2 and 3 .
Statistical analysis For clinical, biochemical, behavioural and process variables the randomisation arms were compared for the patients who completed the 6 and 14 year follow-up with the p values of the corresponding regression coefficients from a multivariate generalised linear model in which the effect of randomisation group was adjusted for age, sex and diabetes duration: ordinary linear regression for continuous variables, logistic regression for binary variables and Poisson regression for count variables with log e (diabetes duration) as offset. Clustering with general practitioners was accounted for by the use of generalised estimating equations (GEE).
The outcomes used in the registry-based follow-up were made with reference to those in the UK Prospective Diabetes Study (UKPDS) [6] : any diabetes-related endpoint, diabetes-related deaths, all-cause mortality, myocardial infarction (MI), stroke, peripheral vascular disease and microvascular disease (ESM Table 1 ). Length of time from diagnosis to death or incident outcomes was analysed with logrank tests and Cox regression models. The proportional hazard assumption was tested by adding the interactions of each of the independent variables in the model with the natural logarithm of time to event to the model. A joint test of these interactions tested the assumption. When one or more of the interactions were significant, the hazard function was estimated separately within strata of the corresponding covariates. A sandwich estimator for the variance was used to account for clustering [19] .
All variables and endpoints were analysed with SAS v9.2 (SAS Institute Inc., Cary, NC, USA) according to the intention-to-treat principle. The level of statistical significance was p<5%. Fig. 1 ). At the end of intervention, the structured-personal-care group had significantly lower levels of HbA 1c (8.4% vs 9.0%, reference range 5.4-7.4%, p<0.0001), systolic BP (145 vs 150 mmHg, p=0.003) and total cholesterol (6.0 vs 6.1 mmol/l, p=0.033) than the routine-care group (Table 2) . At 14 year clinical follow-up, group differences had levelled out, though some of the measures suggest a lasting intervention effect, with a lower level of triacylglycerols, a lower prevalence of (micro)albuminuria, and fewer referrals to a diabetes clinic.
Results
At diabetes diagnosis
At the end of the intervention, metformin was more widely used in the intervention group (24 vs 15%, p<0.001) than in the routine-care group, the only significant group difference in use of drugs observed [15] . In the 14 year follow-up, the two groups received similar but more intensive drug treatment (ESM Table 4 ).
During 19 years of registry-based monitoring, all seven predefined outcomes were experienced by a lower proportion of patients receiving structured personal care compared with patients receiving routine care (Table 3 , Fig. 2 ). Group differences were, however, only statistically significant for any diabetes-related endpoint (HR for structured care 0.83, 95% CI 0.72, 0.97, p=0.016) and fatal or non-fatal MI (HR 0.81, 95% CI 0.68, 0.98, p=0.030). These differences persisted after extensive multivariate adjustment: HR 0.80, 95% CI 0.69, 0.92, p=0.003 and HR 0.81, 95% CI 0.67, 0.99, p=0.039, respectively. Survival was not statistically significantly associated with the intervention (HR 0.94, 95% CI 0.82, 1.08, p=0.40, with multivariate adjustment, Table 3 and Fig. 2 ). In the period after the intervention was terminated, there was a non-significant tendency towards lower incidence rates for structured care for most outcomes, and this propensity was most pronounced for stroke and any diabetes-related endpoint (Fig. 2, Table 3 ). Apart from peripheral vascular disease and microvascular disease the proportion of patients with an outcome was relatively high. For any diabetes-related endpoint the number (%) of patients in the intervention and control groups were 405 (66.3%) and 366 (73.4%). For MI the corresponding figures were 219 (31.5%) and 210 (37.3%), respectively.
Discussion
This long-term follow-up of the DCGP randomised trial of structured personal diabetes care was analysed as an observational study with extensive adjustments for clustering and confounders. During 19 years of monitoring, a statistically significantly reduced risk for MI and any diabetes-related endpoint emerged for patients in the intervention arm. No effect was shown on peripheral vascular disease and microvascular outcomes, possibly because our study was underpowered to detect group differences for these events, which were rare compared with the other outcomes in this study. In comparison with most trials from outpatient clinics [1] [2] [3] [4] 20] , our study population was small and attrition was high, mainly due to the high mortality in our ageing populationbased patient sample. On one hand, the many outcomes caused by the high average age at diagnosis (65 years) endowed the study with statistical strength to analyse group differences in mortality and incidences of cardiovascular outcomes. On the other hand, in elderly patients these outcomes in particular are expected to have causes unrelated to diabetes, and the final results of this study appear as a tradeoff between these underlying preconditions.
When the intervention was terminated, the betweengroup differences in fasting plasma glucose, HbA 1c , total cholesterol and BP were relatively small compared with the UKPDS glucose and hypertension trials [1, 3] . After a further 8 years, these differences in risk factors had levelled out as most risk factors improved in both treatment groups and treatment intensity had increased ( Table 2 , ESM Table 4). The improvements in (micro)albuminuria and fasting triacylglycerols at 14 year follow-up, however, indicates a lasting intervention effect on surrogate outcomes beyond that seen in UKPDS [6] . All things considered, these findings add to the evidence for a legacy intervention effect in type 2 diabetes on long-term development of complications, and extend them to the primary healthcare setting. They also suggest that improved outcomes may be attainable within the framework of a complex intervention with individualised treatment.
Previous research Overall, the effectiveness of different solitary quality-improvement strategies for glycaemic control in type 2 diabetes is modest. We incorporated regular follow-up, prompting of doctors, feedback on individual patients, clinical guidelines and continuing medical education for doctors in our multifaceted intervention because all these elements seem to be effective [14, [21] [22] [23] . Later, all of these aspects of chronic care were included in the chronic care model [24] [25] [26] . On top of this, we added individualised goal setting [27, 28] . In complex interventions the effect cannot easily be ascribed to single elements, but it is likely that the improvements in both risk factors and endpoints can be explained, at least partly, by the combined effect of small changes in process and lifestyle measures, which we were unable to pick up with our relatively simple data collection instruments ( Table 2 ). The intervention probably had too little focus on smoking cessation, increased physical activity and prescription of lipid-lowering drugs (Table 2; ESM Table 2 The mean numbers of diabetes-related consultations last year for structured/routine care at 6 and 14 year follow-up were 5.1/4.4 and 3.9/4.6, respectively No., number Table 4 ), and, in general, the patients might have benefitted from more intensive theory-based patient education and support [29] . In blood glucose trials testing intensive multipharmacological treatment to target, adverse weight gain is common [1, [9] [10] [11] 20] . In the DCGP study, in which it was recommended that treatment goals for risk factors including weight be negotiated by the doctor and patient, an average weight loss was maintained for 14 years in both groups. In the intervention group, doctors had been asked not to start drug treatment before the patients had experienced the effects of their own efforts to shape a new lifestyle [15, 30] . Other lifestyle interventions have been shown to reduce the use of medication for diabetes considerably [31] , and diet may be the most important component of such interventions [32] .
Patients' absolute risk of developing a cardiovascular outcome was greater than in other diabetes trials [1, 3, 6, 9-11, 33, 34] (Table 3) . For MI defined as in the present analyses, a meta-analysis [12] of these trials [1, 10, 11, 34] found event rates of 13.3 and 14.7 per 1,000 patient-years in intervention and control groups, respectively, and HR 0.90 (95% CI 0.82, 0.99). In the DCGP study the corresponding figures were event rates of 27.3 and 33.5 per 1,000 patientyears and HR 0.81 (95% CI 0.67, 0.99) (Table 3) . Thus, the incidence of MI in DCGP was twice that of major cardiovascular outcome studies of intensive glucose control in type 2 diabetes, and the absolute risk reduction for intensive care was four times greater. Relatively old patients may be more compliant than younger patients [35] , and the personalised care may be particularly well taken up by elderly patients, which could contribute to the explanation of our results.
Further strengths and weaknesses The study was originally conducted and reported as a cluster-randomised trial [15] . The present analyses are not described in the protocol, and are therefore interpreted as observational and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations [36] , with adjustment for confounders and clustering.
Our main results rest on long-term follow-up in major Danish registries. The vital status and cause of death could be confirmed for 99.9% and 99.7% of study participants, respectively. The Danish Register of Causes of Death has covered the entire population of Denmark since 1875 [17] , and the Danish National Patient Registry has covered 99.4% of discharges from Danish hospitals since 1977 [37] . From 1995 onwards the registry has also included emergency room and outpatient clinic visits, but the registry has only covered all contacts with hospitals in Denmark since 2007, primarily because registrations from the few and small private specialised hospitals were missing [18] . However, these hospitals are not supposed to be contributors of information about the outcomes in this study. Both registries have changed registration and coding practices on several occasions, and the concepts and definitions of diseases have changed; new diagnostic criteria for MI were introduced in 2000, for example. In the nationwide DCGP study these time-dependent changes in registration are unlikely to cause differential misclassification according to treatment allocation. The validity has not been established for all the registry-based diagnoses in Table 3 , but for MI as primary diagnosis or underlying cause of death the predictive value was 93.6% and the sensitivity was 77.6% in comparison with definite or possible MI as diagnosed in the Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) Project in Denmark [38] . In a small retrospective audit of patient records, the predictive value of the stroke diagnosis in the Danish National Patient Register was 81-86% [39] .
While our registry data in Table 3 are relatively strong, our results in Table 2 from the clinical follow-up of surviving patients must be interpreted in view of the slightly unequal attrition across randomisation groups. Similarly, even for those re-examined at 6 and 14 year follow-up, data may be missing differentially according to outcomes. Estimations of biochemical variables, however, were centralised and quality controlled.
In the registry-based follow-up, detailed information enabled us to make extensive adjustments for a wide spectrum of clinically relevant confounding factors, which, for most Besides clustering, these analyses are adjusted for age, sex and basic school education at diabetes diagnosis. In addition, the 0-6 year and 0-19 year follow-up analyses are adjusted for the following data from diabetes diagnosis: living alone, BMI, hypertension, diagnostic plasma glucose, total cholesterol, fasting triacylglycerols, smoking habits, physical activity and current or former cancer. Similarly, the 6-19 year follow-up analyses are additionally adjusted for the following data from 6 year follow-up: diabetes duration, living alone, BMI, hypertension, HbA 1c , total cholesterol, fasting triacylglycerols, smoking habits, physical activity, current or former cancer and glucose-lowering medication. In the multivariate models, the number of patients with complete data varies from 1,020 to 1,267 or from 522 to 751 when adjusting for diagnostic or 6 year follow-up variables, respectively No., number outcomes, did not change the risk estimates decisively. This may also be because the indirect randomisation was successful (Table 2) , though patient inclusion was done without concealing treatment allocation. It is likely that the results of the DCGP study can be generalised to the general population of patients with type 2 diabetes because: (1) the study was conducted in general practice, where most patients with type 2 diabetes are treated; (2) the study sample was population-based; (3) patients were included with no upper age limit, and the present results from older patients with higher baseline cardiovascular risk may even widen the generalisability of findings from other studies; (4) the elements of the intervention resemble standard procedures in general practice; and (5) a relatively high number of general practices participated. The fact that general practitioners volunteered for the study may have increased the treatment quality in the routine-care group [40] , in which doctors were supposed to do their best and where risk factors were better controlled than in, for example, the conventional treatment group in UKPDS [1] . Between 1988 and 1996 all Danish general practitioners received five diabetes guidelines by post [41] [42] [43] , which may have decreased the size of the effect of the intervention. The same may be said about the considerable movement of patients between practices during the first 14 years after diagnosis (ESM Table 3 ). During the 6 years of intervention, however, a doctor who took over an intervention patient was instructed as for any other intervention doctor.
Clinical implications and perspectives The Steno-2 study was a demonstration trial from secondary care showing convincing risk reductions by multifaceted intervention to achieve strict targets directed at a group at high risk of death and complications [20, 44] . In the Anglo-Danish-Dutch Study of Intensive Treatment In People with ScreenDetected Diabetes in Primary Care (ADDITION) study from general practice a similar target-driven intensivetreatment algorithm applied to patients with type 2 diabetes detected by screening did not reduce cardiovascular events, possibly because the general improvements in diabetes care lowered the achievable differences in treatment between trial arms [45] .
The DCGP intervention was applied in 1989-1995, before a more intensive treatment regimen addressing blood glucose, BP and dyslipidaemia was implemented. Although a healthy survivor effect may have contributed, the effect of these new guidelines on both risk factor level (Table 2 ) and drug treatment (ESM Table 4) at the 14 year follow-up in 2003-2005 seems evident in both treatment arms, which makes the present analyses well suited for estimating the effect of an early intervention starting at diagnosis.
In concert with the 10-year follow-up of the UKPDS study [6] and the non-significant improvements in outcome in the ADDITION study [45] , the DCGP study indicates long-term clinical benefits of early improvement in the metabolic management of older patients with less wellcontrolled type 2 diabetes.
In agreement with the recommendations of contemporary clinical guidelines [13] , the treatment efforts in the DCGP study were individualised, but the clinical guidelines and treatment targets used in the DCGP study should be updated to contemporary standards. Nowadays, patient involvement may be facilitated by a computerised decision aid that includes the calculated risk of complications and many relevant patient characteristics, such as age, sex, social background and comorbidity. In this way the emerging need for personalised treatment in type 2 diabetes, based on both scientific evidence and patient preferences [46] , may be met and even better results obtained than in the present study.
Conclusions
In general practice, 6 years of structured personal care starting from diabetes diagnosis was associated with a reduced risk of MI and any diabetes-related endpoint during 19 years of registry-based monitoring, but survival did not differ between treatment groups. This took place without any overall increase in medication and occurrence of hypoglycaemia, and an average weight loss was sustained. This study is relevant to daily clinical practice because the elements of the complex multifaceted DCGP intervention are relatively easy to implement, and because the study participants were sampled from the general population, with no upper age limit, and were treated in general practice, as is the case for most people with type 2 diabetes. The results indicate that individualisation of both goal setting and choice of pharmacological interventions may be safely included in a multifaceted contemporary treatment regimen. Finally, the results lend support to the assumption that enhanced quality of early diabetes treatment, starting at diabetes diagnosis, is important for lowering the long-term risk of diabetes complications.
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